Momenta Pharmaceuticals, Inc. (MNTA) Receives Consensus Recommendation of “Hold” from Brokerages

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has earned a consensus recommendation of “Hold” from the thirteen ratings firms that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation and ten have assigned a hold recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $14.44.

Several research firms recently issued reports on MNTA. JPMorgan Chase & Co. reissued a “hold” rating and issued a $14.00 target price on shares of Momenta Pharmaceuticals in a research report on Thursday, October 5th. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. ValuEngine cut shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Goldman Sachs Group started coverage on shares of Momenta Pharmaceuticals in a research report on Thursday, September 28th. They set a “neutral” rating and a $18.00 price target on the stock. Finally, Robert W. Baird cut shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price target for the company from $22.00 to $15.00 in a research report on Friday, October 6th.

Shares of Momenta Pharmaceuticals (NASDAQ MNTA) opened at $17.55 on Monday. Momenta Pharmaceuticals has a 12-month low of $11.85 and a 12-month high of $19.90. The stock has a market cap of $1,340.00, a P/E ratio of -21.94 and a beta of 1.66.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.03. Momenta Pharmaceuticals had a negative net margin of 55.61% and a negative return on equity of 16.20%. The business had revenue of $24.09 million for the quarter, compared to analysts’ expectations of $29.58 million. During the same period last year, the company earned ($0.26) earnings per share. The company’s quarterly revenue was down 17.3% on a year-over-year basis. research analysts anticipate that Momenta Pharmaceuticals will post -1.16 EPS for the current fiscal year.

In other news, CEO Craig A. Wheeler sold 35,666 shares of Momenta Pharmaceuticals stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $14.11, for a total transaction of $503,247.26. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Elizabeth Stoner sold 5,500 shares of Momenta Pharmaceuticals stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $13.10, for a total transaction of $72,050.00. Following the sale, the director now owns 13,240 shares in the company, valued at approximately $173,444. The disclosure for this sale can be found here. Insiders have sold 49,505 shares of company stock worth $685,923 in the last quarter. Insiders own 4.40% of the company’s stock.

Several large investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. increased its stake in shares of Momenta Pharmaceuticals by 0.4% in the second quarter. PNC Financial Services Group Inc. now owns 76,863 shares of the biotechnology company’s stock worth $1,299,000 after buying an additional 303 shares during the last quarter. Pinebridge Investments L.P. increased its stake in shares of Momenta Pharmaceuticals by 4.3% in the second quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock worth $149,000 after buying an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in shares of Momenta Pharmaceuticals by 14.9% in the second quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock worth $109,000 after buying an additional 834 shares during the last quarter. Profund Advisors LLC increased its stake in shares of Momenta Pharmaceuticals by 13.1% in the second quarter. Profund Advisors LLC now owns 13,172 shares of the biotechnology company’s stock worth $223,000 after buying an additional 1,530 shares during the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of Momenta Pharmaceuticals by 1.6% in the second quarter. California State Teachers Retirement System now owns 130,075 shares of the biotechnology company’s stock worth $2,198,000 after buying an additional 2,099 shares during the last quarter. Institutional investors and hedge funds own 93.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) Receives Consensus Recommendation of “Hold” from Brokerages” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/08/momenta-pharmaceuticals-inc-mnta-receives-consensus-recommendation-of-hold-from-brokerages.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply